Welcome to Medications.com

Acorda's Next Hurdle - Smartmoney.com

He foresees earnings of 90 cents a share in 2010, based on early Fampridine sales and revenue from Acorda's only other product, Zanaflex, which helps MS ...

http://www.smartmoney.com/barrons... | Posted: Thu Jan 24 16:08:59 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea